Monopar Therapeutics (MNPR) SEC Filings: History & Chart

Monopar Therapeutics Inc.(MNPR)

Biotechnology · Wilmette, IL

$81.26+2.97 (+3.79%)

Delayed quote: Oct 6, 2026, 2:55 PM EDT

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Wilmette, IL

22 employees

www.monopartx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Chandler D. Robinson

View full financials

Form	Filing Date	Accepted	Document
4	Oct 5, 2026	Oct 5, 2026	View filing
4	Oct 2, 2026	Oct 2, 2026	View filing
4	Oct 2, 2026	Oct 2, 2026	View filing
4	Oct 2, 2026	Oct 2, 2026	View filing
4	Sep 28, 2026	Sep 28, 2026	View filing
4/A	Aug 28, 2026	Aug 28, 2026	View filing
4/A	Aug 28, 2026	Aug 28, 2026	View filing
4	Aug 27, 2026	Aug 27, 2026	View filing
4	Aug 27, 2026	Aug 27, 2026	View filing
4	Aug 27, 2026	Aug 27, 2026	View filing
SC 13G/A	Aug 12, 2026	Aug 12, 2026	View filing
SC 13G/A	Aug 12, 2026	Aug 12, 2026	View filing
8-K	Aug 12, 2026	Aug 12, 2026	View filing
10-Q	Aug 12, 2026	Aug 12, 2026	View filing
S-8 POS	Jul 22, 2026	Jul 22, 2026	View filing
S-8 POS	Jul 22, 2026	Jul 22, 2026	View filing
S-8 POS	Jul 22, 2026	Jul 22, 2026	View filing
S-8 POS	Jul 22, 2026	Jul 22, 2026	View filing
S-8	Jul 22, 2026	Jul 22, 2026	View filing
8-K	Jul 22, 2026	Jul 22, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jun 30, 2026	Jun 30, 2026	View filing
3	Jun 30, 2026	Jun 30, 2026	View filing
8-K	Jun 30, 2026	Jun 30, 2026	View filing
8-K	Jun 26, 2026	Jun 26, 2026	View filing
8-K	Jun 23, 2026	Jun 23, 2026	View filing
8-K	May 29, 2026	May 29, 2026	View filing
8-K	May 19, 2026	May 19, 2026	View filing

SEC Filings

Recent Filings